Q3/FY2016 FINANCIAL RESULTS
ENDED DECEMBER 31, 2016

Yasumasa Masuda
Senior Corporate Executive, Chief Financial Officer
Astellas Pharma Inc.
January 31, 2017

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

AGENDA

I Q3/FY2016 Financial Results

II Initiatives to Build Resilience for Sustainable Growth

III Profit Distribution Policy

Q3/FY2016 FINANCIAL RESULTS (CORE BASIS)

(billion yen)	Q3/FY15	Q3/FY16	Change	FY16 FCST*	Achieve-ment	(ref) CER growth
Net sales	**1,065.7**	**1,005.6**	**-5.6%**	**1,300.0**	**77.4%**	+3%
Cost of sales	270.5	250.8	-7.3%			
% of sales	25.4%	24.9%	-0.4 ppt			
SG&A expenses	362.7	336.7	-7.2%			
% of sales	34.0%	33.5%	-0.6ppt			
R&D expenses	165.0	148.3	-10.1%	216.0	68.7%	
% of sales	15.5%	14.7%	-0.7ppt	16.6%		
Amortisation of intangibles	33.2	26.7	-19.3%			
Share of associates/JVs losses	-0.5	-1.3	-			
Core operating profit	**233.9**	**241.8**	**+3.4%**	**274.0**	**88.3%**	+18%
Core profit for the period	**169.4**	**177.2**	**+4.6%**	**202.0**	**87.7%**	

Exchange rate (yen)**	Q3/FY15	Q3/FY16	Change	FY16FCST
USD: Average for the period	122	107	-15	103
EUR: Average for the period	134	118	-16	117
USD: Change from PY end	+0	+4		
EUR: Change from PY end	+1	-5		

Fx impacts		
	Net sales:	-89.6
	Core OP:	-33.6

astellas

* Revised in Oct. 2016
** Exchange rate change +: Yen weakening, - : Yen Strengthening

CER: Constant exchange rate
PY: Previous year

SALES ANALYSIS



*Dermatology business transfer: Amortisation of deferred revenue - PY sales of transferred products

OAB: Overactive bladder, OAB products: Vesicare + Betanis/Myrbetriq/BETMIGA

NHI: National health insurance

CORE OPERATING PROFIT ANALYSIS

(Positive/negative signs show impacts on operating profit)



XTANDI and OAB products growth
Negative impacts by Fx, NHI price revision in Japan
(CER growth: +3%)

COGs ratio decrease: -0.4ppt
Product mix change, etc: -0.3ppt
Fx impacts on unrealized profit elim.: -0.1ppt

SG&A decrease due to Fx
Promotion of cost efficiency

R&D decrease due to Fx
Promotion of cost efficiency

Amortisation decrease: -6.4
Share of associates/JVs losses: -0.8

astellas

FINANCIAL RESULTS (FULL BASIS)

(billion yen)	Q3/FY15	Q3/FY16	Change	FY16FCST*	Achievement
Net sales	**1,065.7**	**1,005.6**	**-5.6%**	**1,300.0**	**77.4%**
Core operating profit	**233.9**	**241.8**	**+3.4%**	**274.0**	**88.3%**
Other income	1.1	6.6			
Other expenses	19.4	17.1			
Operating profit	**215.6**	**231.3**	**+7.3%**	**267.0**	**86.6%**
Financial income	13.8	14.0			
Financial loss	0.9	1.4			
Profit before tax	228.5	243.9	+6.8%	268.0	91.0%
Profit for the period	**164.5**	**178.8**	**+8.7%**	**198.0**	**90.3%**

Other income:
- Q3/FY16 Foreign exchange gain (4.3 bil. yen) recorded

Other expenses:
- Q3/FY16 Loss on sale and disposal of property, plant and equipment (7.7 bil. yen) and impairment loss of other intangible assets (4.1 bil. yen) recorded
- Q3/FY15 (PY) Loss on sale and disposal of property, plant and equipment (8.8 bil. yen) and foreign exchange losses (7.0 bil. yen) recorded

Financial income:
- Q3/FY16 Gain on sale of financial assets (12.7 bil. yen) recorded
- Q3/FY15 (PY) Gain on sale of financial assets (12.1 bil. yen) recorded

astellas

*Revised in Oct. 2016

SALES BY REGION (LOCAL CURRENCY BASIS)

Steady growth in Americas, EMEA and Asia/Oceania on a local currency basis

Japan (billion yen)



- Sales in Japanese market: 358.2 (-7%)
  Decrease due to NHI price revision, etc.

Americas (million USD)



- XTANDI and OAB products growth
- CRESEMBA contribution

EMEA (Europe, the Middle East and Africa) (million EUR)



- XTANDI growth
- Prograf and MYCAMINE increase

Asia/Oceania (billion yen)



- +10% CER growth
  XTANDI and OAB products contribution

Sales by region: based on the location of the seller

SALES IN THREE KEY AREAS

Each franchise showed solid performance on a CER basis

(billion yen)	Q3/FY15	Q3/FY16	Change	(ref) CER growth
Oncology	**242.7**	**232.3**	**-4%**	+8%
XTANDI	188.8	189.2	+0%	+13%
OAB in Urology	**164.9**	**160.9**	**-2%**	+8%
Vesicare	104.8	89.3	-15%	-6%
Betanis/Myrbetriq/BETMIGA	60.1	71.6	+19%	+31%
Transplantation	**157.5**	**142.2**	**-10%**	+0%

Oncology: XTANDI, Tarceva, Eligard and Gonax
Transplantation: Prograf, Advagraf/Graceptor/ASTAGRAF XL

Pursue further penetration in chemo-naive mCRPC

Sales by region



Sales composition by region



Year-on-Year sales growth

Japan: -11%
Americas: +4% (USD basis)
EMEA: +42% (EUR basis)
Asia/Oceania: +68% (CER basis)

mCRPC: Metastatic castration-resistant prostate cancer

OAB FRANCHISE IN UROLOGY

Betanis/Myrbetriq/BETMIGA penetration enhances OAB Franchise

Sales by region



Sales composition ratio by product



Year on Year sales growth

Japan: +9%
EMEA: -2% (EUR basis)
Americas: +10% (USD basis)
Asia/Oceania: +47% (CER basis)

SALES IN JAPANESE MARKET

Sales in Japanese market decreased by 7% due to NHI price revision, etc.
Key products sales steadily expanded



AGENDA

I Q3/FY2016 Financial Results

II Initiatives to Build Resilience for Sustainable Growth

III Profit Distribution Policy

ACHIEVING SUSTAINABLE GROWTH
(same as Strategic Plan 2015-2017 slide)

New products will drive mid-term growth;
Sustainable growth will be reinforced by continuous selective investment in innovation and strengthening of the business foundation



STRATEGIC PRIORITIES AND RECENT ACTIVITIES
(UPDATE FROM PREVIOUS ANNOUNCEMENT)

Maximize the Product Value

- Enhance oncology franchise (XTANDI sales growth, label expansion)
- Maximize OAB franchise (expansion of Vesicare + Betanis/ Myrbetriq/BETMIGA)
- New product launches in many countries

Create Innovation

[Progress of pipeline]

- Approval:
  - LINZESS (IBS-C, JP)
- Filing:
  - Romosozumab (JP)
- P3 trials are steadily ongoing

[New initiative]

- Completion of acquisition of Ganymed Pharmaceuticals
- License agreement with Auration for AU-935 to treat chronic tympanic membrane perforations

Pursue Operational Excellence

[Optimal allocation of resources]

- Transfer of Qutenza to Grünenthal

[Continually enhance organization structure]

- Outsourcing of facility and equipment management support in Japan, and dissolution of Astellas Business Service

IBS-C: Irritable bowel syndrome with constipation

MAXIMIZE THE PRODUCT VALUE

CONTINUOUS INTRODUCTION OF NEW PRODUCTS

EMEA

[Status of XTANDI and BETMIGA]

XTANDI
- Inclusion of TERRAIN data to SmPC
- Post-chemo indication: Launched in 41 countries
- Chemo-naive indication: Launched in 20 countries

BETMIGA:
- Launched in 34 countries

[FY2016 Progress]

XTANDI
- Chemo-naive indication: Launched in Iceland

Japan

[Status of XTANDI and Betanis]

XTANDI
- Launched

Betanis
- Launched

[FY2016 Progress]

Repatha, Micatrio, Kiklin Granules
- Launched

Americas

[Status of XTANDI and Myrbetriq]

XTANDI
- Post-chemo indication: Launched in 14 countries
- Chemo-naive indication: Launched in 10 countries

Myrbetriq:
- Launched in 6 countries

[FY2016 Progress]

XTANDI
- Inclusion of TERRAIN data to label (US)
- Post-chemo indication: Launched in Colombia, Bolivia and Mexico
- Chemo-naive indication: Launched in Colombia and Chile

Myrbetriq:
- Launched in Brazil

Asia/Oceania

[Status of XTANDI and BETMIGA]

XTANDI
- Post-chemo indication: Launched in 11 countries/areas
- Chemo-naive indication: Launched in 7 countries/areas

BETMIGA:
- Launched in 9 countries/areas

[FY2016 Progress]

XTANDI
- Post-chemo indication: Launched in Taiwan, India, Malaysia, Brunei and Thailand
- Chemo-naive indication: Launched in Taiwan, Hong Kong, Malaysia, Brunei and Thailand

BETMIGA:
- Launched in Indonesia



No. of countries/areas where the following have been launched:
XTANDI: Approx. 70
Betanis / Myrbetriq / BETMIGA: Approx. 50

astellas

Underlined items show updates from the previous announcement

CREATE INNOVATION

PIPELINE

ROBUST PIPELINE OF ASTELLAS

Phase 1

- ASG-15ME
- ASP5878
- AGS67E
- ASP4132
- AGS62P1
- ASP6282
- YM311/FG-2216 (JP)
- ASP7398
- ASP6294
- ASP8302
- ASP5094
- ASP4345
- ASP4070
- ASP7266
- ASP0892
- ASP1807/CC8464

Phase 2

- enzalutamide (Breast cancer, HCC)
- AGS-16C3F (Renal cell carcinoma)
- blinatumomab (AMG 103) (Acute lymphoblastic leukemia, JP)
- enfortumab vedotin (ASG-22ME) (Urothelial cancer)
- IMAB362 (Gastroesophageal adenocarcinoma)
- YM311/FG-2216 (Renal anemia, EU)
- ASP8232 (Diabetic nephropathy)
- bleselumab (ASKP1240) (rFSGS)
- peficitinib (ASP015K) (Rheumatoid arthritis, US/EU)
- ASP7962 (Osteoarthritis)
- ASP8062 (Fibromyalgia)
- ASP0819 (Fibromyalgia)
- ASP3662 (Agitation associated with AD)
- ASP1707 (Endometriosis, rheumatoid arthritis)
- CK-2127107 (SMA, COPD)
- RPE cell program (Dry AMD etc.)

Phase 3

- enzalutamide (M0 CRPC, M0 BCR: US/EU/Asia, M1 HSPC, TNBC: US/EU/JP/Asia)
- degarelix (3-month, JP)
- gilteritinib (ASP2215) (AML, US/EU/JP/Asia)
- ASP8273 (NSCLC, US/EU/JP/Asia)
- solifenacin (Pediatric NDO, US/EU)
- solifenacin/mirabegron (Concomitant use, US/EU/Asia)
- mirabegron (Pediatric NDO, EU)
- roxadustat (ASP1517/FG-4592) (Anemia associated with CKD, EU/JP)
- ASP0113/VCL-CB01 (CMV-HCT, US/EU/JP)
- peficitinib (ASP015K) (Rheumatoid arthritis, JP/Asia)
- fidaxomicin (Infectious enteritis: JP, pediatric: EU)
- ipragliflozin/sitagliptin (Fixed dose combination, JP)
- ipragliflozin (Type 1 diabetes, JP)
- linaclotide (Chronic constipation, JP)

Filed

- enzalutamide (Tablet, EU/JP)
- quetiapine (BP-D, JP)
- romosozumab (AMG 785) (Osteoporosis, JP)

THERAPEUTIC AREA:

- Oncology
- Urology, Nephrology
- Immunology, Neuroscience
- Others
- New molecular/biological entity

Outline of the projects are shown. Please refer to pipeline list for details including target disease.

astellas

HCC: Hepatocellular carcinoma, rFSGS: Recurrence of focal segmental glomerulosclerosis, AD: Alzheimer's disease, SMA: Spinal muscular atrophy, COPD: Chronic obstructive pulmonary disease, AMD: Age-related macular degeneration, M0 CRPC: Non-metastatic castration-resistant prostate cancer, M0 BCR: Non-metastatic biochemical recurrence, M1 HSPC: Metastatic hormone sensitive prostate cancer, TNBC: Triple-negative breast cancer, AML: Acute myeloid leukemia, NSCLC: Non-small cell lung cancer, NDO: Neurogenic detrusor overactivity, CKD: Chronic kidney disease, CMV: Cytomegalovirus, HCT: Hematopoietic cell transplant, BP-D: Bipolar disorder depressive episodes

STEADY PROGRESS IN DEVELOPMENT
SUMMARY OF CHANGES FROM OCTOBER 2016 TO JANUARY 2017

enfortumab vedotin
Urothelial cancer

ASP3662
Agitation associated with Alzheimer's disease

romosozumab
Filed in Dec. 2016
Osteoporosis for those at high risk of fracture (Japan)

linaclotide (LINZESS tablets)
Approved in Dec. 2016
Irritable bowel syndrome with constipation (Japan)

Discontinuation (in a part of indications) etc.

ASP7374: Prophylaxis of seasonal influenza (Filed, Japan)
(Exercised the right to terminate the agreement with UMN Pharma.
Withdrew the application for marketing approval based on the comprehensive consideration.)
ASP7373: Prophylaxis of H5N1 influenza (P2, Japan)
(Exercised the right to terminate the agreement with UMN Pharma.)
gilteritinib: Non-small cell lung cancer (P1)
(The phase 1 study was terminated due to adverse events in combination therapy.)
ASP2205: Stress urinary incontinence (P1)

astellas

RECENT HIGHLIGHTS

linaclotide

- Top line results obtained from Japanese Phase 3 study in patients with chronic constipation
  - The study met its primary endpoints.
  - Safety profile was consistent with the previous clinical studies.

ASP0892

- Fast track designation granted from FDA for mitigation of severe hypersensitivity reactions due to peanut allergy
- Phase 1 study ongoing

ONCOLOGY PIPELINE

Stage in the most advanced territory

	Project	Target Cancer	Characteristics	P1	P2	P3
Small molecule	**enzalutamide**	Prostate cancer (M0 CRPC, M0 BCR, M1 HSPC), Breast cancer, Hepatocellular carcinoma	Androgen receptor inhibitor	**PC, TNBC**		
				BC, HCC		
	degarelix	Prostate cancer	GnRH antagonist	**3-month: JP**		
	gilteritinib	Acute myeloid leukemia	FLT3/AXL inhibitor			
	ASP8273	Non-small cell lung cancer	Mutant-selective irreversible EGFR inhibitor			
	ASP5878	Solid tumors	FGFR inhibitor			
	ASP4132	Advanced cancer				
Antibody	**IMAB362**	Gastroesophageal adenocarcinoma	Antibody (target: CLDN18.2)			
	AGS-16C3F	Renal cell carcinoma	Antibody utilizing ADC (target: ENPP3)			
	blinatumomab	Acute lymphoblastic leukemia	Anti-CD19 BiTE			
	enfortumab vedotin (ASG-22ME)	Urothelial cancer	Antibody utilizing ADC (target: Nectin-4)			
	ASG-15ME	Urothelial cancer	Antibody utilizing ADC (target: SLITRK6)			
	AGS67E	Lymphoid malignancy	Antibody utilizing ADC (target: CD37)			
	AGS62P1	Acute myeloid leukemia	Antibody utilizing ADC (target: FLT3)			

astellas

ADC: Antibody-drug conjugate, PC: Prostate cancer, BC: Breast cancer

ENZALUTAMIDE: DEVELOPMENT PROGRESS

Updated underlined items from previous disclosure

	Phase/Region*	Population	Design	P1	P2	P3
Prostate cancer	**P3 US/EU/Asia [PROSPER study]**	**M0 CRPC** Non-metastatic CRPC	Placebo-controlled, combination with ADT, n=1,500	**First Patient In: Nov. 2013**		
	P3 US/EU/Asia [EMBARK study]	**M0 BCR** Non-metastatic prostate cancer, biochemical recurrence	To compare with ADT and combination, n=1,860	**First Patient In: Jan. 2015**		
	P3 US/EU/JP/Asia [ARCHES study]	**M1 HSPC** Metastatic hormone-sensitive prostate cancer	Placebo-controlled, combination with ADT, n=1,100	**First Patient In: Mar. 2016**		
Breast cancer	**P3 US/EU/JP/Asia [ENDEAR study]**	**Triple-negative** Advanced, diagnostic-positive, triple-negative breast cancer	Combination with paclitaxel or monotherapy, versus placebo with paclitaxel, n=780	**Study start on the way**		
	P2 US/EU	**ER/PR positive** Advanced breast cancer that is ER positive or PR positive and HER2 normal	Placebo-controlled, in combination with exemestane, n=240	**Last Patient In: Apr. 2015**		
	P2 US/EU	**HER2 positive** Advanced, androgen receptor-positive, HER2 positive breast cancer	Open-label, n=80	**Last Patient In: Aug. 2016**		
HCC	**P2 US/EU/Asia**	**Hepatocellular carcinoma**	Placebo-controlled, n=144	**Last Patient In: Dec. 2016**		

*The region where the study is performed
ADT: Androgen-deprivation therapy, ER: Estrogen receptor, PR: Progesterone receptor, HER2: Human epidermal growth factor receptor 2

GILTERITINIB: DEVELOPMENT PROGRESS

Updated underlined items from previous disclosure

	Phase/Region*	Population	Design	P1	P2	P3
AML	**P3 Global [ADMIRAL study]**	**Relapsed or refractory** 1st relapsed or refractory, FLT3 mutation positive	Open-label, randomized, monotherapy vs salvage chemo (2:1), n=369	**First Patient In: Oct. 2015**		
	P1/2 US/EU [CHRYSALIS study]	**Relapsed or refractory**	Dose-escalation and expansion, n=258	**Final results presented at ASH2016**		
	P1 JP	**Relapsed or refractory**	Dose-escalation and expansion	**Enrollment completed**		
	P2/3 Global [LACEWING study]	**1st line intensive chemo ineligible** Newly diagnosed, FLT3 mutation positive	Open-label, randomized, 3 arms (monotherapy, combo with azacitidine and azacitidine alone), n=528	**First Patient in: Nov. 2016**		
	P3 Global [MORPHO study]	**HSCT maintenance** FLT3-ITD positive	Double-blind, randomized, monotherapy vs placebo (1:1), n=346	**Under preparation** Collaborating with Blood and Marrow Transplant – Clinical Trial Network (BMT-CTN)		
	P3 Global [GOSSAMER study]	**Post-chemo maintenance** FLT3-ITD positive	Double-blind, randomized, monotherapy vs placebo (2:1), n=354	**Under preparation**		
	P1 US	**1st line intensive chemo eligible** Newly diagnosed	Combination with induction and consolidation chemo			
	P1 JP	**1st line intensive chemo eligible** Newly diagnosed	Combination with induction and consolidation chemo			

astellas

*The region where the study is performed

FLT3: FMS-like tyrosine kinase 3, ITD: Internal tandem duplication

ENFORTUMAB VEDOTIN: DEVELOPMENT PROGRESS -PHASE 2 STUDY TO START IN 2017-

enfortumab vedotin

enfortumab vedotin
Antibody drug conjugate directed against Nectin-4

Target

- Nectin-4 is a type I transmembrane protein that belongs to the Nectin family of adhesion molecules
- Variable, mostly weak or moderate in normal tissue
- Highly expressed in bladder cancer with 83% (434/524) on tissue microarrays were positive, 60% with strong or moderate staining



Development progress

Plan
- Consult with regulatory agencies and pursue registrational-directed development plan
- Phase 2 planned in patients who have been exposed to check point inhibitor therapy

Current Phase 1
- Continue Phase 1 expansion cohorts in other Nectin 4 expressing solid tumors, including NSCLC and ovarian

GANYMED ACQUISITION COMPLETED

IMAB362: Results from Phase 2 FAST Study

Progression-free survival (primary endpoint)



Overall survival



- The most frequent adverse effects observed during the study were vomiting, nausea and neutropenia.

Plan to discuss with regulatory authorities for next steps

Salah-Eddin Al-Batran *et al.* 2016 ASCO Annual Meeting

EOX: Epirubicin, Oxaliplatin, Capecitabine

FY2016 EXPECTED KEY PIPELINE EVENTS

*Subject to internal assessment, decision and regulatory consultation, as appropriate

Data Readouts and Phase Transition*

Data readouts**

solifenacin/mirabegron
Phase 3 long term study (SYNERGY II)

enzalutamide
Phase 2 in ER/PR+ breast cancer

ASP0113
Phase 2 in solid organ transplants*

ASP3662
Phase 2 in PDPN

ASP8232
Phase 2 in DME

gilteritinib
Phase 1/2 final results in AML

ASP8273
Phase 1/2 final results in NSCLC

Phase transition

enzalutamide
TNBC to Phase 3

linaclotide
CC to Phase 3

Filing*

solifenacin
Pediatric OAB (US)

enzalutamide
Tablet (Japan)

degarelix
3-month formulation (Japan)

romosozumab
Osteoporosis (Japan)

quetiapine
BP-D (Japan)

fidaxomicin
CDI (Japan)

Regulatory Decisions

enzalutamide
TERRAIN (US)

enzalutamide
Tablet (EU)

solifenacin
Pediatric OAB (EU)

bixalomer
Granule formulation (Japan)

linaclotide
IBS-C (Japan)

ASP7374***
Seasonal influenza (Japan)

***Exercised the right to terminate the agreement with UMN Pharma

astellas

** Final data readouts or completion of data evaluation
Light gray items indicate completed events

PDPN: Painful diabetic peripheral neuropathy, DME: Diabetic macular edema, AML: Acute myeloid leukemia, NSCLC: Non-small cell lung cancer, TNBC: Triple-negative breast cancer, CC: Chronic constipation, BP-D; Bipolar disorder, depressive episodes, CDI: *Chrostridium difficile* infection, IBS-C, Irritable bowel symptom with constipation

CREATE SOCIAL VALUE

NEW INITIATIVE: PARTICIPATION IN “ACCESS ACCELERATED”

Builds on Company Commitment to improve Access to Health

Access Accelerated:
A global, multi-stakeholder initiative to advance access to non-communicable disease (NCD) prevention, diagnostics and treatment in low-income and lower-middle income countries

Together with 21 other leading pharmaceutical companies and in collaboration with the World Bank Group and the Union for International Cancer Control (UICC), Astellas will seek to find and advance new solutions to address gaps in access for NCDs, and work towards the United Nations Sustainable Development Goal target to reduce premature deaths from NCDs by one-third by 2030.

AGENDA

I Q3/FY2016 Financial Results

II Initiatives to Build Resilience for Sustainable Growth

III Profit Distribution Policy

PROFIT DISTRIBUTION POLICY

- Top priority on investment for growth of Rx business
- Dividends to be increased continuously based on mid- and long-term growth
- Share buybacks to be implemented in a flexible manner

	FY2014	FY2015	FY2016 (Forecast)
Core EPS	69.37 yen	92.12 yen	95.60 yen
Dividends per Share	30 yen	32 yen	34 yen (planned)
ROE	10.5%	15.0%	-
DOE	5.1%	5.4%	-
Share Buybacks*	38 million shares (58.2 billion yen)	68 million shares (119.3 billion yen)	Implemented in a flexible manner 30 million shares (45.9 billion yen) (in Oct. – Dec.)
Cancellation of Treasury Shares	25 million shares	38 million shares	68 million shares (in Jun.)

astellas

*Excluding amounts for the buyback of shares consisting less than one unit

REALIZE SUSTAINABLE GROWTH

Resiliently respond to the changing environments and aim for sustainable growth

- Business goes favorably, driven by XTANDI and OAB products
- Continue investing in R&D for creating innovation that is source of future growth
- Work toward higher quality and efficiency of operations through optimization of resources, enhancement of organizational structure and further promotion of cost efficiency

Sales (billion yen)



astellas

APPENDIX

RECONCILIATION OF FULL BASIS TO CORE BASIS

(billion yen)

	FY15 APR. - DEC.			FY16 APR. - DEC.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Sales	**1,065.7**	**-**	**1,065.7**	**1,005.6**	**-**	**1,005.6**
Cost of sales	270.5	-	270.5	250.8	-	250.8
Gross profit	**795.2**	**-**	**795.2**	**754.8**	**-**	**754.8**
SG&A expenses	362.7	-	362.7	336.7	-	336.7
R&D expenses	165.0	-	165.0	148.3	-	148.3
Amortisation of intangible assets	33.2	-	33.2	26.7	-	26.7
Share of losses of associates and joint ventures	-0.5	-	-0.5	-1.3	-	-1.3
Other income *1	1.1	-1.1	-	6.6	-6.6	-
Other expense *1	19.4	-19.4	-	17.1	-17.1	-
Operating profit	**215.6**	**18.3**	**233.9**	**231.3**	**10.5**	**241.8**
Finance income *2	13.8	-12.1	1.7	14.0	-12.7	1.3
Finance expense *2	0.9	-0.4	0.6	1.4	-0.4	1.0
Profit before tax	**228.5**	**6.6**	**235.1**	**243.9**	**-1.8**	**242.1**
Income tax expense	63.9	1.8	65.7	65.1	-0.2	64.9
Profit for the period	**164.5**	**4.8**	**169.4**	**178.8**	**-1.6**	**177.2**

*1. “Other income” and “Other expense” are excluded from Full basis results.
“Other income” and “Other expense” include gain/loss on sale and disposal of property, plant and equipment, impairment losses for other intangible assets, restructuring costs, litigation costs and net foreign exchange gains/losses, etc.

*2. Gain/loss on sale of available-for-sale (“AFS”) and impairment losses of AFS included in “Finance income” and “Finance expense” are excluded from Full basis results.

MAXIMIZE THE VALUE OF ENZALUTAMIDE FOR PROSTATE CANCER PATIENTS



P. Mulders *et al. EAU2012,* modified by Astellas

* Radiotherapy, prostatectomy
** Metastatic at the time of diagnosis

PSA: Prostate-specific antigen

GILTERITINIB: TREATMENT LANDSCAPE IN AML



astellas

7+3: Cytarabine + idarubicin or daunorubicin, LoDAC: Low dose cytarabine, FLAG-Ida: Fludarabine + cytarabine + G-CSF + idarubicin, MEC: Mitoxantrone + etoposide + cytarabine

ON THE FOREFRONT OF HEALTHCARE CHANGE